Skip to Main Content

Paper Details

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Lancet Diabetes Endocrinol
384
2018
ELIXA, EXSCEL, GLP, GLP-1 receptor, Glucagon-like peptide-1 (GLP-1) receptor, LEADER, SUSTAIN 6, angina, cardiovascular, cardiovascular events, exenatide, glucagon-like peptide-1 receptor, glucose, heart failure, hypoglycaemia, liraglutide, lixisenatide, medullary thyroid cancer, myocardial infarction, non-fatal myocardial infarction, non-fatal stroke, pancreatic cancer, pancreatitis, patient, patients, semaglutide, type 2 diabetes
Author NameAffiliation
Peter MerrillDuke Clinical Research Institute, Duke University School of Medicine
John B BuseUniversity of North Carolina School of Medicine
Juliana C N ChanChinese University of Hong Kong
Nayyar Iqbal
Bernard ZinmanLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
Adrian F HernandezDuke Clinical Research Institute, Duke University School of Medicine
  • 1 - 6

Datasets

Dataset
Description
Source Link
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
Release 1.2